Alnylam Pharmaceuticals: JPMorgan cuts target price to $254 from $369
ALNY•JPMorgan cut its target price for Alnylam Pharmaceuticals to $254 from $369.
Related News

Nasdaq washout still awaits confirmation
QQQ•

Red Hat expands Microsoft partnership to advance virtualization on Azure
MSFT•

Global-E continues growth in third quarter of 2026 and raises outlook
GLBE•

CG Oncology: Guggenheim raises target price to $120 from $89
CGON•

Broadridge names Lauren Boyman chief marketing and communications officer
BR•